VANCOUVER, BC — September 3, 2025 — Leads & Copy — Zero Candida Technologies Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2), a Femtech company focused on women’s gynecological health, has released its financial and operating results for the three and six months ended June 30, 2025. The results, reported in Canadian dollars and in accordance with IFRS, are available on SEDAR+.
Eli Ben-Haroosh, Chairman & CEO, noted that Q2 was crucial for advancing the company’s device toward human use and establishing its regulatory and clinical strategy. Discussions with hospitals and pharmaceutical companies have underscored the clinical need and commercial potential of ZCT’s technology, aligning with the call for safer, cost-effective healthcare therapies.
Device progress included advanced validation and design refinements. Regulatory pathway efforts involve ongoing documentation for the FDA’s De Novo pathway and B2B/B2C strategies. Discussions with major U.S. hospitals and pharmaceutical companies continue to support clinical and commercial demand, as global regulators tighten oversight on chemical-based health products and warn about antifungal resistance.
Zero Candida’s primary focus remains on developing the ZC–01 device and pre-clinical validation, with no revenues generated yet. Operating expenses for Q2 2025 were $0.31 million, related to R&D, prototype refinement, and corporate development, compared to $0.35 million in 2024. For the six months ended June 30, 2025, operating expenses were $0.67 million, down from $0.91 million in 2024.
As of June 30, 2025, cash and cash equivalents were $0.46 million, up from $0.24 million as of December 31, 2024. Total assets were $2.77 million, with working capital of $1.53 million. Management believes these resources are sufficient for ongoing programs, regulatory activities, and operations for at least the next 12 months.
Eli Ben Haroosh, CEO & Founder, info@zero-candida.com
Victoria Gamble, investors@zero-candida.com, (647) 874 3767
Source: Zero Candida Technologies
Source: Zero Candida Technologies
